Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency – Three consecutive cases and review of the literature

Mostrar otras versiones (1)

Patients lacking humoral response have been suggested to develop a less severe COVID-19, but there are some reports with a prolonged, relapsing or deadly course. From April 2020, there is growing evidence on the benefits of COVID-19 convalescent plasma (CCP) for patients with humoral immunodeficienc...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado-Fernández, Marcial, García-Gemar, Gracia Mar, Fuentes-López, Ana, Muñoz-Pérez, Manuel Isidro, Oyonarte-Gómez, Salvador, Ruíz-García, Ignacio, Martín-Carmona, Jessica, Sanz-Cánovas, Jaime, Castaño-Carracedo, Manuel Ángel, Reguera-Iglesias, José María, Ruíz-Mesa, Juan Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877207/
https://www.ncbi.nlm.nih.gov/pubmed/33741148
http://dx.doi.org/10.1016/j.eimc.2021.01.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877207/
https://www.ncbi.nlm.nih.gov/pubmed/33741148
http://dx.doi.org/10.1016/j.eimc.2021.01.013

Ejemplares similares